Advanced NanoTherapies Secures Over $31M Series B to Deliver First-of-its-Kind Dual-Drug (Paclitaxel and Sirolimus) Nanoparticle-Coated Balloon Platform for Vascular Treatment
Financing supports the approval of U.S. Investigational Device Exemption (IDE), coronary clinical advancement, and expansion into below-the-knee peripheral (BTK) applications. SANTA CLARA, Calif., June 2, 2026 /PRNewswire/ -- Advanced NanoTherapies, Inc. (ANT), a clinical-stage medtech...
Financing supports the approval of U.S. Investigational Device Exemption (IDE), coronary clinical advancement, and expansion into below-the-knee peripheral (BTK) applications. SANTA CLARA, Calif., June 2, 2026 /PRNewswire/ -- Advanced NanoTherapies, Inc. (ANT), a clinical-stage medtech...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.